Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | HTR2C | P28335 | 7/20 | 0.56 |
| ▸ | HTR6 | P50406 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | QDPR | P09417 | 2/20 | 0.44 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5323553 | 0.82 | HTR2C (0.57) | SIGMAR1HTR2CHTR6MAPTHTR1B | |
| SCHEMBL28688462 | 0.80 | SIGMAR1 (0.69) | SIGMAR1HTR2CHTR6MAPTHTR1B | |
| Hydrochloric Acid SCHEMBL28678896 | 0.78 | HTR2C (0.70) | SIGMAR1HTR2CHTR6MAPTHTR1B | |
| SCHEMBL24670316 | 0.77 | SIGMAR1 (0.42) | SIGMAR1HTR2CHTR6MAPTHTR1B | |
| SCHEMBL29768429 | 0.75 | QDPR (0.47) | SIGMAR1HTR2CHTR6MAPTHTR1B | |
| SCHEMBL23215043 | 0.75 | QDPR (0.47) | SIGMAR1HTR2CHTR6MAPTHTR1B | |
| SCHEMBL5539735 | 0.74 | SIGMAR1 (0.61) | SIGMAR1HTR2CQDPRINPPL1 | |
| SCHEMBL15770669 | 0.74 | HRH3 (0.44) | SIGMAR1HTR2CHTR6MAPTHTR1B | |
| SCHEMBL531984 | 0.73 | SIGMAR1 (1.00) | SIGMAR1HTR2CHTR6MAPTHTR1B | |
| SCHEMBL11436251 | 0.73 | HTR2C (0.44) | SIGMAR1HTR2CHTR6MAPTHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005117882-A9 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | INCYTE CORP (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2005117882-A2 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | INCYTE CORPORATION (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | INCYTE CORPORATION | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | MMP9, MMP17, MMP25 | SIGMAR1 4814/4885HTR2C 2955/4885HTR6 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.